Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP30663 single ascending dose extension study in healthy male volunteers
NL-OMON49415Phase 1Not yet recruiting
- Sponsor
- Acesion Pharma
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AP30663 in Atrial fibrillation (AFib), sponsored by Acesion Pharma. Primary endpoints: Treatment-related adverse events, Vital signs, temperature, laboratory safety data, and ECG changes and 3 more. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
AP30663
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON49415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49415.